Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria or Symptomatic Dermographism.
Description: Safety of a single dose of CDX-0159 as determined by adverse events
Measure: Safety as assessed by the incidence and severity of adverse events Time: From Day 1 through week 12Description: The change from baseline in critical temperature thresholds over time as determined by provocation testing using the TempTest®
Measure: For patients with Cold Contact Urticaria, Change in Critical Temperature Thresholds (CTT) Time: From Day 1 to Day 85Description: The change from baseline in provocation thresholds over time as determined by provocation testing using the FricTest®
Measure: For patients with Symptomatic Dermographism, change in provocation thresholds Time: From Day 1 to Day 85Description: Changes from baseline and percentage of responders for the UCT and modified UCT
Measure: Changes from baseline in Urticaria Control Test (UCT) Time: From Day 1 to Day 85Description: Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in Stem Cell Factor
Measure: Blood Biomarkers Time: From Day 1 to Day 85Description: Pre-treatment and post-treatment blood samples will be collected and analyzed for changes in tryptase
Measure: Blood Biomarkers Time: From Day 1 to Day 85Description: CDX-0159 concentrations will be measured.
Measure: Pharmacokinetic Evaluation Time: From Day 1 to Day 85Description: Patients will be monitored for the development of anti-drug antibodies.
Measure: Immunogenicity Evaluation Time: From Day 1 to Day 85Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports